AXIM Biotechnologies, Inc. (AXIM)
USD 0.0
(17.65%)
USD 0.0
(17.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.79 Million USD | -49.3% |
| 2022 | 4.66 Million USD | -40.15% |
| 2021 | 7.78 Million USD | 61.16% |
| 2020 | 4.83 Million USD | -28.18% |
| 2019 | 6.72 Million USD | 28.84% |
| 2018 | 5.22 Million USD | 65.62% |
| 2017 | 3.15 Million USD | -13.65% |
| 2016 | 3.65 Million USD | -63.65% |
| 2015 | 10.04 Million USD | 1886.89% |
| 2014 | 505.72 Thousand USD | 356.08% |
| 2013 | 110.88 Thousand USD | 90.4% |
| 2012 | 58.23 Thousand USD | 355.19% |
| 2011 | 12.79 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 477.04 Thousand USD | 67.01% |
| 2024 Q1 | 349.33 Thousand USD | -47.07% |
| 2023 FY | 2.36 Million USD | -49.3% |
| 2023 Q3 | 598.11 Thousand USD | -15.48% |
| 2023 Q4 | 660.04 Thousand USD | 10.35% |
| 2023 Q1 | 718.03 Thousand USD | -37.56% |
| 2023 Q2 | 707.65 Thousand USD | -1.44% |
| 2022 FY | 4.66 Million USD | -40.15% |
| 2022 Q2 | 1.05 Million USD | -6.45% |
| 2022 Q4 | 1.14 Million USD | -12.83% |
| 2022 Q1 | 1.13 Million USD | -32.8% |
| 2022 Q3 | 1.31 Million USD | 24.47% |
| 2021 Q3 | 3.22 Million USD | 56.18% |
| 2021 FY | 7.78 Million USD | 61.16% |
| 2021 Q1 | 810.64 Thousand USD | -62.65% |
| 2021 Q2 | 2.06 Million USD | 154.85% |
| 2021 Q4 | 1.68 Million USD | -47.75% |
| 2020 Q1 | 1.85 Million USD | 33.99% |
| 2020 Q4 | 2.17 Million USD | 70.53% |
| 2020 Q3 | 1.27 Million USD | 92.03% |
| 2020 FY | 4.83 Million USD | -28.18% |
| 2020 Q2 | 662.86 Thousand USD | -64.22% |
| 2019 Q1 | 2.3 Million USD | 159.51% |
| 2019 FY | 6.72 Million USD | 28.84% |
| 2019 Q4 | 1.38 Million USD | 16.04% |
| 2019 Q3 | 1.19 Million USD | -35.58% |
| 2019 Q2 | 1.84 Million USD | -19.81% |
| 2018 Q2 | 1.34 Million USD | -34.26% |
| 2018 Q1 | 2.04 Million USD | 92.35% |
| 2018 FY | 5.22 Million USD | 65.62% |
| 2018 Q4 | 888.73 Thousand USD | -5.34% |
| 2018 Q3 | 938.87 Thousand USD | -30.29% |
| 2017 Q2 | 439.5 Thousand USD | -3.62% |
| 2017 Q1 | 456.01 Thousand USD | -31.86% |
| 2017 FY | 3.15 Million USD | -13.65% |
| 2017 Q4 | 1.06 Million USD | -10.73% |
| 2017 Q3 | 1.19 Million USD | 171.48% |
| 2016 Q2 | 490.64 Thousand USD | -47.86% |
| 2016 Q4 | 669.26 Thousand USD | -56.86% |
| 2016 Q1 | 940.97 Thousand USD | -85.08% |
| 2016 FY | 3.65 Million USD | -63.65% |
| 2016 Q3 | 1.55 Million USD | 216.22% |
| 2015 Q3 | 1.68 Million USD | 6.83% |
| 2015 Q2 | 1.57 Million USD | 221.72% |
| 2015 FY | 10.04 Million USD | 1886.89% |
| 2015 Q1 | 488.81 Thousand USD | 33.01% |
| 2015 Q4 | 6.3 Million USD | 275.39% |
| 2014 Q2 | 52.26 Thousand USD | 416.4% |
| 2014 FY | 505.72 Thousand USD | 356.08% |
| 2014 Q4 | 367.5 Thousand USD | 187.24% |
| 2014 Q3 | 127.94 Thousand USD | 144.8% |
| 2014 Q1 | 10.12 Thousand USD | -76.44% |
| 2013 Q4 | 42.96 Thousand USD | 303.69% |
| 2013 Q2 | 40.62 Thousand USD | 144.01% |
| 2013 Q1 | 16.65 Thousand USD | 11.85% |
| 2013 FY | 110.88 Thousand USD | 90.4% |
| 2013 Q3 | 10.64 Thousand USD | -73.8% |
| 2012 Q1 | 15.51 Thousand USD | 76.37% |
| 2012 Q3 | 12.6 Thousand USD | -17.33% |
| 2012 Q2 | 15.24 Thousand USD | -1.73% |
| 2012 FY | 58.23 Thousand USD | 355.19% |
| 2012 Q4 | 14.88 Thousand USD | 18.14% |
| 2011 Q4 | 8794.00 USD | 119.85% |
| 2011 FY | 12.79 Thousand USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | 4000.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -108.948% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 44.658% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 90.558% |
| Nascent Biotech, Inc. | 2.22 Million USD | -25.135% |
| Rebus Holdings, Inc. | 664 Thousand USD | -320.234% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 92.51% |
| Qrons Inc. | 643.67 Thousand USD | -333.503% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -616.273% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 95.142% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -571.6% |
| Skye Bioscience, Inc. | 13.54 Million USD | 79.403% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 96.785% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 43.261% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -966.137% |
| SQZ Biotechnologies Company | 85.61 Million USD | 96.741% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 4.316% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -85.789% |
| Mesoblast Limited | 5.9 Million USD | 52.722% |
| Marizyme, Inc. | 19.23 Million USD | 85.497% |
| Genus plc | 147.7 Million USD | 98.111% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 68.216% |
| Pharming Group N.V. | 225.49 Million USD | 98.763% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -36.201% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -107.996% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 66.538% |
| ContraFect Corporation | 56.88 Million USD | 95.095% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 36.708% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -88.697% |
| IMV Inc. | 37.7 Million USD | 92.6% |
| MultiCell Technologies, Inc. | 567.42 USD | -491662.187% |
| ONE Bio Corp. | 6.44 Million USD | 56.698% |
| Accustem Sciences Inc. | 3.74 Million USD | 25.519% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 96.753% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -424.541% |
| Q BioMed Inc. | 3.43 Million USD | 18.805% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 88.71% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -6.197% |
| Biomind Labs Inc. | 994.18 Thousand USD | -180.669% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.191% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -58.572% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 58.465% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -49.668% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 11261.428% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 82.571% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -52.055% |
| GB Sciences, Inc. | 1.42 Million USD | -96.434% |
| Alpha Cognition Inc. | 9.7 Million USD | 71.25% |
| HST Global, Inc. | 140.9 Thousand USD | -1880.283% |
| CSL Limited | 3.44 Billion USD | 99.919% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -148.052% |
| Halberd Corporation | 74.84 Thousand USD | -3628.33% |
| Enzolytics Inc. | 2.17 Million USD | -28.027% |
| Agentix Corp. | 1.37 Million USD | -103.415% |
| Resverlogix Corp. | 12.71 Million USD | 78.049% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 23.567% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.818% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -167.276% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -16.026% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -76.677% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 18.051% |
| AVAX Technologies, Inc. | 7.31 Million USD | 61.83% |
| Zenith Capital Corp. | 8.94 Million USD | 68.798% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.662% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -15917.203% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -13.645% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1526.945% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -45.263% |
| Kadimastem Ltd | 2.41 Million USD | -15.777% |
| Helix BioMedix, Inc. | 1.97 Million USD | -41.496% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 74.323% |
| BioStem Technologies, Inc. | 22.97 Million USD | 87.855% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1437.514% |
| LadRx Corporation | 3.81 Million USD | 26.797% |
| Cell Source, Inc. | 4.32 Million USD | 35.488% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -202.147% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -202.147% |
| NovAccess Global Inc. | 2.46 Million USD | -13.118% |
| Affymax, Inc. | 39.38 Million USD | 92.915% |
| Itoco Inc. | 919.14 Thousand USD | -203.582% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 34.165% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -149.362% |
| Mobile Lads Corp. | 554.54 Thousand USD | -403.179% |
| CytoDyn Inc. | 18.05 Million USD | 84.548% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -10986.483% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1167.895% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -96.533% |
| SYBLEU INC | 160.87 Thousand USD | -1634.477% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -53.627% |
| International Stem Cell Corporation | 5.27 Million USD | 47.062% |
| Bioxytran, Inc. | 3.82 Million USD | 26.957% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -5200.629% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -13616.546% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 92.306% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -72.457% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -279.21% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 10.307% |
| Neutra Corp. | 243.82 Thousand USD | -1044.428% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 84.016% |
| PureTech Health plc | 144.59 Million USD | 98.07% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 86.382% |
| IXICO plc | 4.7 Million USD | 40.719% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 68.281% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.63% |
| CSL Limited | 3.89 Billion USD | 99.928% |
| Cellectis S.A. | 97.32 Million USD | 97.133% |